PATENT CLAIM ANALYSIS

Application Number: 15756043
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Claim (Index 85):
The method of any one of  claims 81 - 84 , wherein the agent exhibits one or more activities selected from the group consisting of:\n (a) increasing the number of tumor infiltrating CD3 +  T cells; (b) inhibiting Siglec-7 binding to one or more Siglec-7 ligands; (c) decreasing cellular levels of Siglec-7 in peripheral immune cells (d) reducing the number of non-tumorigenic CD14 +  myeloid cells, optionally wherein the non-tumorigenic CD14 +  myeloid cells are tumor infiltrating cells or optionally wherein the non-tumorigenic CD14 +  myeloid cells are present in blood; (e) reducing the number of non-tumorigenic CD14 +  myeloid cells, optionally wherein the non-tumorigenic CD14 +  myeloid cells are tumor infiltrating cells or optionally wherein the non-tumorigenic CD14 +  myeloid cells are present in the tumor; (f) reducing PD-L1 levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (g) reducing PD-L2 levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (h) reducing CD11b levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (i) reducing B7-H3 levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (j) reducing CD200R levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (k) reducing CD163 levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (l) reducing CD206 levels in one or more cells, optionally wherein the one or more cells are non-tumorigenic myeloid-derived suppressor cells (MDSC); (m) decreasing tumor growth rate of solid tumors; (n) reducing tumor volume; (o) increasing efficacy of one or more PD-1 inhibitors; (p) increasing efficacy of one or more checkpoint inhibitor therapies and/or immune-modulating therapies, optionally wherein the one or more checkpoint inhibitor therapies and/or immune-modulating therapies target one or more of CTL4, the adenosine pathway, PD-L1, PD-L2, OX40, TIM3, LAG3, or any combination thereof; (q) inhibiting differentiation, survival, and/or one or more functions of non-tumorigenic myeloid-derived suppressor cells (MDSC); (r) inducing cell death of one or more myeloid-derived suppressor cells (MDSC); (s) increasing proliferation of T cells in the presence of non-tumorigenic myeloid-derived suppressor cells (MDSC).

Metadata:
- Claim Count in Document: 16.0
- Percentile: 88.0
- Lexical Diversity: 1.46667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14565370', '14021777', '15222849', '15182327', '15222848']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7952380165777176
- 35 USC 102 Novelty (BERT): 0.577632344897771
- Combined Prediction Score: 0.773477449409723
- Mean Citation Score: 461.736258
- Max Citation Score: 500.8059
- Similarity Product: 335.3219641952992

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test